Alzheimer&#039;s disease

Improving Clinical Diagnosis of Alzheimer’s Disease - Part 1

Many subtypes of disease exist under the umbrella of dementia with Alzheimer’s disease (AD) being the most common. AD-related dementia is...

Jan 10, 2022

Testimonial: Value of the β-Amyloid ratio and other CSF biomarkers in the Erlangen Score interpretation algorithm

By Prof. Dr. Piotr Lewczuk - Two groups of established cerebrospinal fluid (CSF) biomarkers reflect two major pathological alterations in Alzheimer's...

Jan 7, 2022

Webinar replay - Possible applications for novel CSF biomarkers

At Fujirebio we have been hosting a webinar series with leading expert speakers dedicated to current topics in the field of Alzheimer's disease...

Dec 16, 2021

Webinar series - Current topics in Alzheimer's disease diagnostics

We have been hosting a series of 3 webinars with leading expert speakers and dedicated to current topics in the field of Alzheimer's Disease...

Dec 16, 2021

Towards an easy plasma pTau 181 detection

Blood-based Alzheimer’s disease (AD) biomarker testing could be used as a simple, accessible, and scalable approach to help support the diagnosis of...

Nov 19, 2021

Webinar replay - Preparing for the future of plasma based Alzheimers disease diagnostics

At Fujirebio we are hosting a webinar series with leading expert speakers dedicated to current topics in the field of Alzheimer's disease diagnostics...

Nov 18, 2021

Video - The interest of automated testing for all four CSF biomarkers

In less than 2 minutes, this video explains the advantages of automated biomarker testing for all four CSF biomarkers, over other available testing...

Nov 18, 2021

Webinar replay - CSF-based biomarkers to support the diagnosis of Alzheimer’s disease

At Fujirebio we are hosting a webinar series with leading expert speakers dedicated to current topics in the field of Alzheimer's disease diagnostics...

Oct 29, 2021

The Fujirebio Neuro Center of Excellence

The Fujirebio Neuro Center of Excellence has been founded with the objective of rising to this challenge. It is a research and development hub focused...

Oct 28, 2021

Booklet - First edition of our new clinical booklet "A few drops of insight can lead to an ocean of understanding"

Early diagnosis of Alzheimer's disease is crucial. The desire to tackle neurodegenerative diseases by always finding earlier diagnostic solutions and...

Sep 21, 2021

Video - Ratio calculation of Aβ1-42 and Aβ1-40 offers essential information about the buildup of amyloid pathology in a patient's brain

This 2 minute video explains why and how a ratio calculation of the two amyloid proteins, Aβ1-42 and Aβ1-40, offers particularly essential information...

Sep 20, 2021

Video - Daniel's story about his early testing and diagnosis of Alzheimers disease

Daniel lives in Stockholm, Sweden, and was diagnosed with Alzheimer’s disease when he was still in his early 50's. In this 6-minute video we follow...

Jun 23, 2021

Influence of automation on Aβ1-42/Aβ1-40 ratio and its use

Automation is an important step in the direction of more standardization as it limits the number of manual handling steps and therefore minimizes...

Mar 16, 2020

Comparison of Aβ1-42/Aβ1-40 ratio with other ratios

CSF Aβ1-42/Aβ1-40 is a tool to normalize values of patients with different amyloid levels, as other ratios might be seen more as interpretation tools...

Mar 2, 2020

How to work with Aβ1-42/Aβ1-40 ratio

One cause of discordant results can be the preanalytical conditions, e.g. when laboratories use tubes that bind certain proteins. Aβ1-42 adsorption is...

Feb 5, 2020

Improvement of AD risk scores by use of the Aβ1-42/Aβ1-40 ratio

Different scores have been developed to provide an interpretation of biomarker results for AD diagnosis or risk prediction. Here we will give two...

Jan 20, 2020

Aβ1-42/Aβ1-40 ratio for interpretation of discordant results

By use of the Aβ1-42/Aβ1-40 ratio, discordant results (i.e. when amyloid and tau biomarkers are not concordant) can be improved. However, while the...

Jan 9, 2020

Use of the Aβ1-42/Aβ1-40 ratio to improve accuracy of AD diagnosis

It is widely agreed that, since cerebrospinal fluid (CSF) is in direct contact with the central nervous system (CNS), analytes measured in this body...

Nov 22, 2019

What is Alzheimer's disease?

Alzheimer’s disease, which is the most common form of dementia, is an incurable degenerative disease. Neurons in certain parts of the brain are...

Sep 30, 2019

Alzheimer biomarkers, PHF-Tau

Product number not specified (raw material) -

One of the key hallmarks to Alzheimer’s disease is the formation of neurofibrillary tangles. These are aggregates of hyperphosphorylated Tau protein, also referred to as paired helical filaments (PHF-Tau).

Detail

Alzheimer biomarkers, Tau

Product number not specified (raw material) -

Tau proteins are mainly present in neurons and play a role in axonal microtubule stability. An increase of Tau is considered as a biomarker for neuronal death and as such often included in diagnostic algorithms for Alzheimer’s disease.

Detail

INNOTEST^® hTAU Ag

Product number 81572 -

Solid-phase enzyme immunoassay for the quantitative determination of Tau protein in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® hTAU Ag

Product number 81579 -

Solid-phase enzyme immunoassay for the quantitative determination of Tau protein in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® NPTX2

Product number 80908 -

A solid-phase enzyme immunoassay for the quantitative determination of neuronal pentraxin-2 (NPTX2) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® PHOSPHO-TAU (181P)

Product number 81581 -

Solid-phase enzyme immunoassay for the quantitative determination of phospho-tau(181P) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® PHOSPHO-TAU(181P)

Product number 81574 -

Solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® sTREM2

Product number 81056 -

INNOTEST sTREM2 is a solid-phase enzyme immunoassay for the quantitative determination of soluble Triggering Receptor Expressed on Myeloid cells 2 (sTREM2) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® β-AMYLOID(1-40)

Product number 81585 -

Solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-40) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® β-AMYLOID(1-40)

Product number 80462 -

Solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-40) in human cerebrospinal fluid (CSF) in the clinical setting of dementia diagnosis.

Detail

INNOTEST^® β-AMYLOID(1-42)

Product number 81576 -

Solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-42) in human cerebrospinal fluid (CSF).

Detail

INNOTEST^® β-AMYLOID(1-42)

Product number 81583 -

Solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-42) in human cerebrospinal fluid (CSF).

Detail

Lumipulse^® G pTau 181

Product number 230350 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of β-amyloid1-40 in human cerebrospinal fluid (CSF).

Detail

Lumipulse^® G Total Tau

Product number 230312 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of total Tau in human cerebrospinal fluid (CSF).

Detail

Lumipulse^® G β-Amyloid 1-40

Product number 231524 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of β-amyloid1-40 in human cerebrospinal fluid (CSF).

Detail

Lumipulse^® G β-Amyloid 1-42

Product number 230336 -

Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of β-amyloid in human cerebrospinal fluid.